Pharmaceuticals, Biotechnology and Life Sciences
Novartis has been cleared in Europe for Tafinlar combined with Mekinist (dabrafenib with trametinib) to treat patients with BRAF V600-with advanced non-small cell lung cancer (NSCLC).
AstraZeneca’s trial treating relapsed ovarian cancer patients with olaparib met its primary endpoint, the company said Tuesday.
English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.
Stellar Biotechnologies and biopharmaceuticals manufacturer Amaran Biotechnology have entered into an exclusive multi-year supply agreement regarding studies of immunotherapies for various cancers, including breast cancer.
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview
Novartis could get first targeted treatment for patients with BRAF non-small cell lung cancer if European Medicines Agency (EMA) approves Tafinlar+Mikinist combination.
PMV Pharmaceuticals, Inc., a cancer focused developer of p53-targeted small molecule drugs, has completed a Series B financing round bagging $74 million.
Syros scientists discovered alterations in regulatory regions of the genome in tumor-associated macrophages in a subset of patient tissues, the company said on Tuesday. Because these alterations are unique to the immunosuppressive state, they could point to genes critical for driving immunosuppression in the tumor microenvironment, as well as potential drug targets to reactivate the immune system to fight cancer.
Botswana will be a centert for southern and east Africa for hematology-oncology treatment, as it will get a new $100…
The growing incidence of more Western lifestyle diseases such as cardiovascular disease (CVD), cancer, diabetes and respiratory disease, in addition to infectious and parasitic illness, will present the pharmaceutical industry in Africa with a business opportunity of $40.8 billion in 2019.